Cargando…
The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial
OBJECTIVE: Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been reported to have beneficial effects in patients with IgA nephropathy (IgAN). Although DHA and EPA have different mechanisms of action, no study to date has assessed their individual actions in patients with IgAN. This st...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820033/ https://www.ncbi.nlm.nih.gov/pubmed/29093399 http://dx.doi.org/10.2169/internalmedicine.9155-17 |
_version_ | 1783301301675753472 |
---|---|
author | Moriyama, Takahito Kumon, Saeko Kamiyama, Takahiro Karasawa, Kazunori Uchida, Keiko Nitta, Kosaku |
author_facet | Moriyama, Takahito Kumon, Saeko Kamiyama, Takahiro Karasawa, Kazunori Uchida, Keiko Nitta, Kosaku |
author_sort | Moriyama, Takahito |
collection | PubMed |
description | OBJECTIVE: Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been reported to have beneficial effects in patients with IgA nephropathy (IgAN). Although DHA and EPA have different mechanisms of action, no study to date has assessed their individual actions in patients with IgAN. This study therefore analyzed the effects administering DHA in addition to EPA for the treatment of IgAN. METHODS: Twenty-one IgAN patients who were being treated with EPA (1,800 mg/day) were switched to EPA (1,860 mg/day) and DHA (1,500 mg/day). The changes in their clinical parameters from 6 months before to 6 months after switching treatment were analyzed. RESULTS: The triglyceride levels did not change during treatment with EPA alone, but tended to decrease-although not to a statistically significant extent-after the switch. The patients’ low-density-lipoprotein cholesterol, blood pressure, proteinuria, and hematuria levels were similar before and after switching. The estimated glomerular filtration rate (eGFR) tended to decrease during EPA therapy, but became stable after switching and the median %⊿eGFR changed from -7.354% during EPA therapy to +1.26% during the 6 months after switching to EPA and DHA therapy (p=0.00132), and renal the function remained stable for another 6 months. Moreover, the median %⊿eGFR during the 6 months after switching was significantly higher in comparison to IgAN patients who were treated with EPA alone as a control (-3.26%, p=0.0361). No clinical parameters were independently associated with a stable renal function without switching to DHA/EPA. CONCLUSION: The addition of DHA to EPA stabilized the renal function of IgAN patients, and it seemed that there were pleiotropic effects beyond the improvement of the clinical parameters. |
format | Online Article Text |
id | pubmed-5820033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-58200332018-02-22 The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial Moriyama, Takahito Kumon, Saeko Kamiyama, Takahiro Karasawa, Kazunori Uchida, Keiko Nitta, Kosaku Intern Med Original Article OBJECTIVE: Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been reported to have beneficial effects in patients with IgA nephropathy (IgAN). Although DHA and EPA have different mechanisms of action, no study to date has assessed their individual actions in patients with IgAN. This study therefore analyzed the effects administering DHA in addition to EPA for the treatment of IgAN. METHODS: Twenty-one IgAN patients who were being treated with EPA (1,800 mg/day) were switched to EPA (1,860 mg/day) and DHA (1,500 mg/day). The changes in their clinical parameters from 6 months before to 6 months after switching treatment were analyzed. RESULTS: The triglyceride levels did not change during treatment with EPA alone, but tended to decrease-although not to a statistically significant extent-after the switch. The patients’ low-density-lipoprotein cholesterol, blood pressure, proteinuria, and hematuria levels were similar before and after switching. The estimated glomerular filtration rate (eGFR) tended to decrease during EPA therapy, but became stable after switching and the median %⊿eGFR changed from -7.354% during EPA therapy to +1.26% during the 6 months after switching to EPA and DHA therapy (p=0.00132), and renal the function remained stable for another 6 months. Moreover, the median %⊿eGFR during the 6 months after switching was significantly higher in comparison to IgAN patients who were treated with EPA alone as a control (-3.26%, p=0.0361). No clinical parameters were independently associated with a stable renal function without switching to DHA/EPA. CONCLUSION: The addition of DHA to EPA stabilized the renal function of IgAN patients, and it seemed that there were pleiotropic effects beyond the improvement of the clinical parameters. The Japanese Society of Internal Medicine 2017-11-01 2018-01-15 /pmc/articles/PMC5820033/ /pubmed/29093399 http://dx.doi.org/10.2169/internalmedicine.9155-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Moriyama, Takahito Kumon, Saeko Kamiyama, Takahiro Karasawa, Kazunori Uchida, Keiko Nitta, Kosaku The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial |
title | The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial |
title_full | The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial |
title_fullStr | The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial |
title_full_unstemmed | The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial |
title_short | The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial |
title_sort | renoprotective effects of docosahexaenoic acid as an add-on therapy in patients receiving eicosapentaenoic acid as treatment for iga nephropathy: a pilot uncontrolled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820033/ https://www.ncbi.nlm.nih.gov/pubmed/29093399 http://dx.doi.org/10.2169/internalmedicine.9155-17 |
work_keys_str_mv | AT moriyamatakahito therenoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT kumonsaeko therenoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT kamiyamatakahiro therenoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT karasawakazunori therenoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT uchidakeiko therenoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT nittakosaku therenoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT moriyamatakahito renoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT kumonsaeko renoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT kamiyamatakahiro renoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT karasawakazunori renoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT uchidakeiko renoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial AT nittakosaku renoprotectiveeffectsofdocosahexaenoicacidasanaddontherapyinpatientsreceivingeicosapentaenoicacidastreatmentforiganephropathyapilotuncontrolledtrial |